Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment.
Young-Hyuck Im
No relevant relationships to disclose
Petro Odarchenko
No relevant relationships to disclose
Daniela Grecea
No relevant relationships to disclose
Dmitry Komov
No relevant relationships to disclose
Chernobay Valentynovych Anatoliy
No relevant relationships to disclose
Sudeep Gupta
No relevant relationships to disclose
Yaroslav V. Shparyk
No relevant relationships to disclose
Priscilla B. Caguioa
No relevant relationships to disclose
Anatoly Makhson
No relevant relationships to disclose
Dmitriy Krasnozhon
No relevant relationships to disclose
Rubi Khaw Li
No relevant relationships to disclose
Dzmitry Noryk
No relevant relationships to disclose
Yurii Oleksiiovych Vinnyk
No relevant relationships to disclose
Gia Nemsadze
No relevant relationships to disclose
Ho Ung Kim
Employment or Leadership Position - Celltrion
Sang-Joon Lee
Employment or Leadership Position - Celltrion
Consultant or Advisory Role - Statistical Consulting (U)
Stock Ownership - Celltrion